Samuel Niles is an associate in the Corporate Department of Latham & Watkins.
Samuel is a generalist corporate lawyer who advises entrepreneurs, management teams, financial institutions and other corporate clients on a wide variety of matters involving corporate and securities law, including:
Registered public offerings, including initial public offerings (IPOs) and follow-on equity and debt offerings
Alternative financing transactions, including Private Investments in Public Equity (PIPEs), At-the-Market offerings (ATMs) and special purpose acquisition company (SPAC) IPO and de-SPAC transactions
Emerging company matters through all stages of growth, including early-stage formation and strategy, venture capital equity and debt financings, employment matters, commercial and strategic transactions and corporate governance matters
Experience
Samuel's recent experience includes advising:
Public Offerings
The underwriters in Aerovate Therapeutics’ US$140 million IPO of common stock
Aziyo Biologics in its US$50 million IPO of Class A and Class B common stock
Lyra Therapeutics in its US$60 million IPO of common stock
Homology Medicines in its:
US$166 million initial public offering of common stock
Multiple follow-on public offerings of common stock
The underwriters in connection with Rubius Therapeutics':
US$275 million IPO of common stock
US$200 follow-on public offering of common stock
The underwriters in connection with Kaleido Biosciences'
US$75 million IPO of common stock
Subsequent follow-on public offerings of common stock
The underwriters in resTORbio’s US$98 million IPO of common stock
Ra Pharma in its US$150 million follow-on public offering of common stock
ContraFect in its US$52 million public offering of common stock and warrants to purchase common stock and concurrent private placement of common stock and warrants to purchase common stock
The underwriter in Collegium Pharmaceutical’s US$125 million registered public offering of senior convertible notes
The underwriters in Blueprint Medicines’ US$345 million follow-on public offering of common stock
The underwriter in Akebia Therapeutics' US$89 million follow-on public offering of common stock
The underwriters in Clearside Biomedical's US$85 million follow-on public offering of common stock
Alternative Financing Transactions
Everest Consolidator in its US$172 million SPAC IPO of units
Aziyo Biologics in its US$14 million PIPE financing
Lyra Therapeutics in its US$100 million PIPE financing
Rafael Holdings in its US$104 million PIPE financing
The sales agent in Neptune Wellness’ US$50 million ATM program of common stock under the US-Canadian multijurisdictional disclosure system
Affiliates of Ally Bridge Group in multiple venture capital, PIPE, and other alternative investments
Mallinckrodt on certain securities matters relating to its chapter 11 bankruptcy proceedings
Emerging Company Matters
Indigo Agriculture in its US$535 million Series F financing and on prior investment rounds
Dewpoint Therapeutics in its US$150 million Series C financing, and on prior investment rounds and formation and general corporate matters
Kojin Therapeutics in its US$60 million Series A financing and on formation and general corporate matters
KSQ Therapeutics in its US$80 million Series C financing and on in prior investment rounds and on general corporate matters
Biothea Pharma in its Series A financing
CIBO Technologies in its US$30 million Series C financing and on prior investment rounds and general corporate matters
Jnana Therapeutics in its US$50 million Series B financing and on general corporate matters
Ring Therapeutics in its US$117 million Series B financing and on general corporate matters
Cellarity in its US$123 million Series B financing and on general corporate matters
Atea Pharmaceuticals in its US$215 million Series D financing
Centrexion Therapeutics in its US$67 million Series D financing and on general corporate matters
Various other early-stage venture-backed start-up companies, in financing, securities, employment, intellectual property, and general corporate governance matters
Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.
